Clinical trial for Heart Failure NYHA Class II
Official title PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
ClinicalTrials.gov ID: NCT05934487
What this study is testing
- What it's testing
- The study will see if the Cordella sensor is safe and helps manage heart‑failure symptoms in patients with NYHA class II or III heart failure.
- Who it's for
- Adults with diagnosed heart failure who are in NYHA class II or III.
- What's involved
- Participants will have a sensor implanted in a pulmonary artery to measure pressure. They will receive daily data and may be part of different treatment groups, including a group that can adjust their own care based on the data.
- Time commitment
- The trial lasts about 12 months, with regular clinic visits and ongoing monitoring of the sensor data.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Subject has given written informed consent 2. Male or female, at least 18 years of age 3.
- HFrEF (EF \< 50%): Subject has been on stable medications maximized to the subject's tolerance of ACE-I or ARB or ARNI, MRA, beta-blockers, and...
- HFpEF (EF ≥ 50%): Subject has been on stable medication maximized to the subject's tolerance of SGLT2i as determined by the study investigator for at...
You likely can't join if
- ACC/AHA Stage D refractory HF (including a known history of \>24 hours of IV inotropic therapy to support circulation within the past 6 months (other...
- people with history of recurrent pulmonary embolism (≥2 episodes within 5 years prior to Screening Visit) and/or deep vein thrombosis in the femoral...
- people with a resting systolic blood pressure \<90 mmHg and/ or severe pre-capillary pulmonary hypertension with a pulmonary artery systolic pressure...
- people who have had a major cardiovascular (CV) event (e.g., myocardial infarction, stroke) within 3 months of the Screening Visit
- Unrepaired severe valvular disease
- people with significant congenital heart disease that has not been repaired and would prevent implantation of the Cordella PA Sensor or...
See the full eligibility criteria
- Subject has given written informed consent 2. Male or female, at least 18 years of age 3. Diagnosis and treatment of HF (regardless of LVEF) for ≥ 3 months and NYHA Class II HF (NYHA II Cohort) or NYHA III (NYHA III...
- HFrEF (EF \< 50%): Subject has been on stable medications maximized to the subject's tolerance of ACE-I or ARB or ARNI, MRA, beta-blockers, and SGLT2i as determined by the study investigator for at least 30 days prior...
- HFpEF (EF ≥ 50%): Subject has been on stable medication maximized to the subject's tolerance of SGLT2i as determined by the study investigator for at least 30 days prior to Screening/Enrollment 5.
- ACC/AHA Stage D refractory HF (including a known history of \>24 hours of IV inotropic therapy to support circulation within the past 6 months (other than relation to a procedure))
- people with history of recurrent pulmonary embolism (≥2 episodes within 5 years prior to Screening Visit) and/or deep vein thrombosis in the femoral or IJ vein used for access (\< 3 month prior to Screening Visit)
- people with a resting systolic blood pressure \<90 mmHg and/ or severe pre-capillary pulmonary hypertension with a pulmonary artery systolic pressure of ≥70 mm/Hg with pulmonary capillary wedge pressure ≤ 15 mmHg at the...
- people who have had a major cardiovascular (CV) event (e.g., myocardial infarction, stroke) within 3 months of the Screening Visit
- Unrepaired severe valvular disease
- people with significant congenital heart disease that has not been repaired and would prevent implantation of the Cordella PA Sensor or mechanical/tissue right heart valve(s)
- people with known coagulation disorders
- people with a hypersensitivity or allergy to platelet aggregation inhibitors including aspirin, clopidogrel, prasugrel, and ticagrelor
- Known history of life-threatening allergy to contrast dye.
- people whereby RHC is contraindicated
- people with an active infection at the Cordella Sensor Implant Visit
- people with a GFR \<20 ml/min or who are on chronic renal dialysis
- Implanted with Cardiac Resynchronization Therapy-Pacemaker (CRT-P) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D), or having undergone mitral/tricuspid valve repair/replacement within 90 days or catheter...
- Received or are likely to receive an advanced therapy (e.g., durable mechanical circulatory support or lung or heart transplant) in the next 24 months
- people who are pregnant or breastfeeding
- people who are unwilling or deemed by the Investigator to be unwilling to comply with the study protocol, or people with a history of non-compliance
- Severe illness, other than heart disease, which would limit survival to \<2 years
- people whose clinical condition, in the opinion of the Investigator, makes them an unsuitable candidate for the study
- people enrolled in another investigational trial with an active Treatment Arm
- Subject who is in custody by order of an authority or a court of law
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Los Angeles, California, United States
- San Francisco, California, United States
- Miami, Florida, United States
- Pensacola, Florida, United States
- Atlanta, Georgia, United States
- Downers Grove, Illinois, United States
- Palos Park, Illinois, United States
- Indianapolis, Indiana, United States
- Kansas City, Kansas, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Howell, Michigan, United States
- Minneapolis, Minnesota, United States
- Saint Cloud, Minnesota, United States
- Kansas City, Missouri, United States
- New York, New York, United States
- Stony Brook, New York, United States
- Durham, North Carolina, United States
- Cincinnati, Ohio, United States
+ 18 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Los Angeles, California, United States; San Francisco, California, United States; Miami, Florida, United States; Pensacola, Florida, United States; Atlanta, Georgia, United States and 32 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.